Oncolytics Biotech Inc ONCY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ONCY is a good fit for your portfolio.
News
-
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
-
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
-
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
-
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
-
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
-
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
-
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
-
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Trading Information
- Previous Close Price
- $1.06
- Day Range
- $1.03–1.07
- 52-Week Range
- $0.88–3.39
- Bid/Ask
- $1.02 / $1.10
- Market Cap
- $79.94 Mil
- Volume/Avg
- 62,129 / 378,227
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 27
Comparables
Valuation
|
Metric
|
ONCY
|
IMU
|
SGEN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.80 | 3.05 | 16.92 |
Price/Sales | — | — | 18.61 |
Price/Cash Flow | — | — | — |
Price/Earnings
ONCY
IMU
SGEN
Financial Strength
|
Metric
|
ONCY
|
IMU
|
SGEN
|
|---|---|---|---|
Quick Ratio | 8.24 | 5.46 | 1.96 |
Current Ratio | 9.01 | 5.73 | 2.67 |
Interest Coverage | — | — | — |
Quick Ratio
ONCY
IMU
SGEN
Profitability
|
Metric
|
ONCY
|
IMU
|
SGEN
|
|---|---|---|---|
Return on Assets (Normalized) | −78.92% | −41.83% | −13.05% |
Return on Equity (Normalized) | −114.13% | −45.23% | −17.35% |
Return on Invested Capital (Normalized) | −115.78% | −47.05% | −16.86% |
Return on Assets
ONCY
IMU
SGEN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nlwfxkwdln | Zdgbz | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wgfxgrkh | Qpwtly | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Snxhngj | Mndmbg | $99.5 Bil | |
MRNA
| Moderna Inc | Kqgtpxjj | Ttyd | $38.8 Bil | |
ARGX
| argenx SE ADR | Glrpghs | Xfftk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lyvrwtj | Rzbnn | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bxrqwqwh | Nskfzhq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jmpbnhvd | Rhlkn | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zdbpphvpw | Fngtl | $12.5 Bil | |
INCY
| Incyte Corp | Fkyhkpsc | Lqmqxj | $11.6 Bil |